Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REP. WYDEN DRAFTING MEDICAID/V-A FLAT PHARMACEUTICAL REBATE PLAN AS AMENDMENT TO REP. MONTGOMERY’s BILL; GENERIC DRUG REBATES WOULD BE TRIMMED, IF NOT DELETED

Executive Summary

Rep. Wyden (D-Ore.) is drafting a Medicaid/Veterans Affairs pharmaceutical flat rebate bill that also would reduce or even eliminate rebates required for generic drug products. Wyden is drafting the measure as an amendment to Rep. Montgomery's (D-Miss.) bill, HR 2890, that would roll back V-A drug prices to levels in place before enactment of the Medicaid rebate program. The Montgomery bill is one of three rebate-related bills slated for a July 31 House Energy & Commerce/Health Subcommittee hearing. Wyden would obtain savings to offset the generic provision by keeping the flat rebate set at 22% of the average manufacturer's price for a drug product. Legislation (HR 5614) already introduced by Rep. Slattery (D- Kan.), as well as a similar Senate bill (S 2950) introduced by Sen. Chafee (R-R.I.), would replace Medicaid's "best price" rebate formula with a flat rebate set at 22% in 1993, 19% in 1994, 17% in 1995 and 16% thereafter ("The Pink Sheet" July 13, p. 3). Those figures are based on the Congressional Budget Office's projection of the level of flat rebate needed to obtain the same savings as under best prices. Wyden is said to disagree with this approach because it makes the flat rebate "budget neutral" to manufacturers' continuing increases in best prices, and thus he believes it has the effect of condoning those increases. Wyden projects that keeping the rebate at 22% would result in additional savings of $1 bil. through 1996. On the other hand, Wyden is described as believing that reducing rebates for generic drugs is merited due to the continuing strong price competition among generics. Wyden's bill would extend his proposed flat rebate to V-A, other purchasers using the V-A's federal supply schedule, Public Health Service-funded clinics and Medicare "disproportionate share" hospitals. The latter are hospitals designated by Medicare as serving disproportionately large amounts of Medicaid and other low-income patients. The July 31 hearing will consider an earlier Wyden measure (HR 3405) that would extend Medicaid discounted prices to PHS clinics as well as the Montgomery and Slattery bills. At a July 14 informal briefing previewing the hearing, subcommittee Counsel Andy Schneider advised that any rebate legislation emerging from the Commerce Committee this year would probably go to the House floor under a "suspension of the rules." Under this procedure, no amendments are allowed but a two-thirds vote is required for passage. Thus, Schneider advised parties interested in the rebate program to make their views known prior to the subcommittee and full committee markups. On the Senate side, the V-A Committee has scheduled a July 23 health markup that is expected to include rebate proposals from Sens. Simpson (R-Wyo.) and Rockefeller (D-W.Va.).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel